Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
April 2014, Vol 5, No 3
April 2014, Vol 5, No 3
Value Propositions
By
Jayson Slotnik, JD, MPH
Value Propositions
,
Value Peer-spectives
April 2014, Vol 5, No 3
Value Propositions from April 2014.
Read Article
Dovitinib Active but Not Superior to Sorafenib in Patients with Metastatic Renal Cancer
By
Jayson Slotnik, JD, MPH
In the Literature
April 2014, Vol 5, No 3
Therapies targeting vascular endothelial growth factor (VEGF) and mTOR signaling pathways are standard first-line and second-line treatment options for patients with metastatic renal-cell carcinoma. However, an unmet medical need exists for patients who had previously received VEGF-targeted and mTOR inhibitor therapies.
Read Article
Rituximab Active in Nodular Lymphocyte-Predominant Hodgkin Lymphoma
By
Jayson Slotnik, JD, MPH
In the Literature
April 2014, Vol 5, No 3
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare type of Hodgkin lymphoma that represents approximately 5% of all cases. Unlike classic Hodgkin lymphoma, the malignant cells of NLPHL universally express CD20. Because rituximab (Rituxan) is an anti-CD20 monoclonal antibody, it has been evaluated as a treatment option for this patient population.
Read Article
Personalizing Targeted Treatment Possible for Advanced Breast Cancer
By
Jayson Slotnik, JD, MPH
In the Literature
April 2014, Vol 5, No 3
Metastatic breast cancer is a leading cause of death worldwide, with almost 40,000 women in the United States succumbing to the disease in 2013. Although advances in the treatment of breast cancer have been made, metastatic disease is still largely considered incurable. In a prospective, multicenter, molecular-screening study, researchers investigated whether the identification of individual genomic alterations could lead to personalized targeted therapy in women with advanced breast cancer (André F, et al.
Lancet Oncol
. 2014;15:267-274).
Read Article
14 New Genetic Markers Predict Risk for Prostate Cancer
By
Neil Canavan
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
April 2014, Vol 5, No 3
A mutation in any 1 of a suite of DNA repair pathway genes may predict not only the risk for familial prostate cancer, but also indicate the presence of a particular aggressive form of the disease, according to results of a new UK study from the Institute of Cancer Research in London.
Read Article
Routine Cervical Cancer Screening Warranted Beyond Age 64
By
Rosemary Frei, MSc
Cervical Cancer
,
Personalized Medicine
April 2014, Vol 5, No 3
Results of a new study investigating the probability of a cervical cancer diagnosis among women aged 65 to 83 years using data from the UK Cervical Screening Call/Recall System indicate that the current practice may need to be changed.
Read Article
Promise of Personalized Care Hinges on Reimbursement Reform
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
April 2014, Vol 5, No 3
The promise of big data–driven personalized healthcare mandates reform of the oncology reimbursement system, suggested Jeffery C. Ward, MD, Medical Oncologist, Swedish Cancer Institute, Edmonds, WA, in a recent commentary.
Read Article
Implications of the ACA for Cancer Care
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
April 2014, Vol 5, No 3
Hollywood, FL—The Affordable Care Act (ACA) is in its infancy, but it is already changing oncology practice, said panelists at the 2014 National Comprehensive Cancer Network (NCCN) Conference roundtable discussion. The consequences of the ACA include the changing composition of oncology patients, the risk pool of the exchanges, new payment and reimbursement models, acquisition fever, and oncology workforce demands, the panelists said.
Read Article
Page 3 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma